
UK-based Rosemont Pharmaceuticals has appointed a new chair with a wealth of experience in the US pharma market.
Irish-born Sharon Curran (pictured above) will take up the role with Rosemont, a company that manufactures and specializes in novel, Rx oral liquid medicines for patients who have difficulty swallowing due to conditions such as dysphagia, stroke or dementia.
Ms Curran has held extensive senior and executive leadership roles in healthcare including non-executive board positions at businesses across Europe and the USA, notably AbbVie (NYSE: ABBV) in Chicago.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze